Detailed Information on Publication Record
2009
Progression of diabetic nephropathy vs. cross-talk between genetic variability in the RAAS system and its pharmacologic blockade: Results of 7-years observational pharmacogenetic study
KAŇKOVÁ, Kateřina, Soňa ŠTĚPÁNKOVÁ, Lukáš PÁCAL, Marcela PONGRÁCOVÁ, Jan MUŽÍK et. al.Basic information
Original name
Progression of diabetic nephropathy vs. cross-talk between genetic variability in the RAAS system and its pharmacologic blockade: Results of 7-years observational pharmacogenetic study
Name in Czech
Progression of diabetic nephropathy vs. cross-talk between genetic variability in the RAAS system and its pharmacologic blockade: Results of 7-years observational pharmacogenetic study
Authors
Edition
IDF 2009 Montreal, 2009
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30202 Endocrinology and metabolism
Country of publisher
Canada
Confidentiality degree
není předmětem státního či obchodního tajemství
Organization unit
Faculty of Medicine
Keywords in English
renin-angiotensin system
Tags
International impact, Reviewed
Změněno: 19/3/2010 12:51, prof. MUDr. Kateřina Kaňková, Ph.D.
V originále
There are multiple determinants of progression of diabetic nephropathy (DN) such as metabolic and blood pressure control, albumin/proteinuria and genetics. One of the crucial pathogenic mechanisms is the over-activation of renin - angiotensin - aldosterone system (RAAS). We hypothesized that certain functional variants in the RAAS represent significant independent risk factors influencing the DN progression in subjects. Additionally, therapeutic benefit, predominantly based on the RAAS blockade - ACEIs and angiotensin receptor blockers (ARBs), might also be influenced by genetic variability within the RAAS components. Using clinical data collated during prospective follow-up of the cohort of diabetics with DN and advanced multivariate stat. methods we quantified the pathogenic contribution of main DN risk factors: (i) cumulative glycemia, blood pressure and proteinuria, (ii) other metabolic factors such as body weight and lipids in relation to the DN pharmacotherapy (i.e. cumulative received dose of ACEIs and ARBs and carrier state of selected candidate (pharmaco)genetic variants.
In Czech
There are multiple determinants of progression of diabetic nephropathy (DN) such as metabolic and blood pressure control, albumin/proteinuria and genetics. One of the crucial pathogenic mechanisms is the over-activation of renin - angiotensin - aldosterone system (RAAS). We hypothesized that certain functional variants in the RAAS represent significant independent risk factors influencing the DN progression in subjects. Additionally, therapeutic benefit, predominantly based on the RAAS blockade - ACEIs and angiotensin receptor blockers (ARBs), might also be influenced by genetic variability within the RAAS components. Using clinical data collated during prospective follow-up of the cohort of diabetics with DN and advanced multivariate stat. methods we quantified the pathogenic contribution of main DN risk factors: (i) cumulative glycemia, blood pressure and proteinuria, (ii) other metabolic factors such as body weight and lipids in relation to the DN pharmacotherapy (i.e. cumulative received dose of ACEIs and ARBs and carrier state of selected candidate (pharmaco)genetic variants.
Links
| NR9443, research and development project |
|